The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Common corruption of the mTOR signaling network in human tumors
Open accessAbstract
The mammalian target of rapamycin (mTOR) is responsive to numerous extracellular and intracellular cues and, through the formation of two physically and functionally distinct complexes, has a central role in the homeostatic control of cell growth, proliferation and survival. Through the aberrant activation of mTOR signaling, the perception of cellular growth signals becomes disconnected from the processes promoting cell growth, and this underlies the pathophysiology of a number of genetic tumor syndromes and cancers. Here, we review the oncogenes and tumor suppressors comprising the regulatory network upstream of mTOR, highlight the human cancers in which mTOR is activated and discuss how dysregulated mTOR signaling provides tumors a selective growth advantage. In addition, we discuss why activation of mTOR, as a consequence of distinct oncogenic events, results in diverse clinical outcomes, and how the complexity of the mTOR signaling network might dictate therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Mechanism of activation of protein kinase B by insulin and IGF-1.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,004
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Mathew, R., Karantza-Wadsworth, V., & White, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2254 · Cited by 1,798
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Self-citationSabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
(2000) · PubMed · Cited by 1,445
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
Regulation of TORC1 by Rag GTPases in nutrient response
Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P., & Guan, K.-L. (2008) · Nature Cell Biology · doi:10.1038/ncb1753 · Cited by 1,349
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237
Self-citationPRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · cited 4×
“Both complexes have additional subunits that are not required for core complex function, including PRAS40 (Proline-Rich Akt Substrate of 40 kDa) in mTORC1 and PRR5 (proline-rich protein 5, also called PROTOR1) or PRR5L (PRR5-like, also called PROTOR2) in mTORC2 (Pearce et al., 2007; Sancak et al., 2007; Vander et al.,…”
BackgroundInfluentialInsulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citationCurrent development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Kim, D.-H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V. P., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 961
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s
Frias, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W., Sculley, T., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 695
Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Hidayat, S., Yoshino, K.-I., Hara, K., Tanaka, N., Avruch, J., & Yonezawa, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200665200 · Cited by 682
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth
Shaw, R. J. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01972.x · Cited by 644
IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway
Lee, D.-F., Kuo, H.-P., Chen, C.-T., Hsu, J.-M., Chou, C.-K., Wei, Y., Sun, H.-L., Li, L.-Y., Ping, B., Huang, W.-C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.058 · Cited by 637
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 614
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., & Guan, K. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.119 · Cited by 610
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
Akt Maintains Cell Size and Survival by Increasing mTOR-dependent Nutrient Uptake
Edinger, A. L., & Thompson, C. B. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-12-0584 · Cited by 589
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 586
The Pharmacology of mTOR Inhibition
Guertin, D. A., & Sabatini, D. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe24 · Cited by 568
TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function
Schalm, S. S., Fingar, D. C., Sabatini, D. M., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00329-4 · Cited by 520
Yang, Q., Inoki, K., Ikenoue, T., & Guan, K.-L. (2006) · Genes & Development · doi:10.1101/gad.1461206 · Cited by 517
The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 511
Self-citationFacchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A. C., Mao, Y., Miao, R. Q., et al. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.120 · Cited by 509
Identification of a Conserved Motif Required for mTOR Signaling
Schalm, S. S., & Blenis, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00762-5 · Cited by 482
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Identification of Protor as a novel Rictor-binding component of mTOR complex-2
Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deak, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 464
Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Restraining PI3K: mTOR signalling goes back to the membrane
Harrington, L. S., Findlay, G. M., & Lamb, R. F. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.003 · Cited by 366
Pantuck, A. J., Seligson, D. B., Klatte, T., Yu, H., Leppert, J. T., Moore, L., O'Toole, T., Gibbons, J., Belldegrun, A. S., & Figlin, R. A. (2007) · Cancer · doi:10.1002/cncr.22677 · Cited by 350
Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
Carrière, A., Cargnello, M., Julien, L.-A., Gao, H., Bonneil, É., Thibault, P., & Roux, P. P. (2008) · Current Biology · doi:10.1016/j.cub.2008.07.078 · Cited by 336
Gera, J. F., Mellinghoff, I. K., Shi, Y., Rettig, M. B., Tran, C., Hsu, J.-H., Sawyers, C. L., & Lichtenstein, A. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309999200 · Cited by 331
Targeting the mTOR signaling network in cancer
Chiang, G. G., & Abraham, R. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.001 · Cited by 327
Zhou, X., Tan, M., Stone Hawthorne, V., Klos, K. S., Lan, K.-H., Yang, Y., Yang, W., Smith, T. L., Shi, D., & Yu, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0112 · Cited by 312
James, M. F., Han, S., Polizzano, C., Plotkin, S. R., Manning, B. D., Stemmer-Rachamimov, A. O., Gusella, J. F., & Ramesh, V. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01581-08 · Cited by 306
Self-citationmTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285 · cited 1×
“Translation of the pro-survival Bcl-2 family member MCL-1 can be stimulated by mTORC1 activity, and this mechanism has been shown to contribute to cell survival in a mouse lymphoma model (Mills et al., 2008).”
BackgroundFeedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2
Manning, B. D., Logsdon, M. N., Lipovsky, A. I., Abbott, D., Kwiatkowski, D. J., & Cantley, L. C. (2005) · Genes & Development · doi:10.1101/gad.1314605 · Cited by 235
Self-citationThe mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
Zhou, L., Huang, Y., Li, J., & Wang, Z. (2010) · Medical Oncology · doi:10.1007/s12032-009-9201-4 · Cited by 225
Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis
Davies, D. M., Johnson, S. R., Tattersfield, A. E., Kingswood, J. C., Cox, J. A., McCartney, D. L., Doyle, T., Elmslie, F., Saggar, A., de Vries, P. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmc072500 · Cited by 211
Wang, X., Beugnet, A., Murakami, M., Yamanaka, S., & Proud, C. G. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.7.2558-2572.2005 · Cited by 205
mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C.-L., Vera, D. R., & Shaw, R. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900465106 · Cited by 205
Rojo, F., Najera, L., Lirola, J., Jiménez, J., Guzmán, M., Sabadell, M. D., Baselga, J., & Cajal, S. R. Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1560 · Cited by 205
Vega, F., Medeiros, L. J., Leventaki, V., Atwell, C., Cho-Vega, J. H., Tian, L., Claret, F.-X., & Rassidakis, G. Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3018 · Cited by 196
López-Lago, M. A., Okada, T., Murillo, M. M., Socci, N., & Giancotti, F. G. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01578-08 · Cited by 184
Expression of mTOR signaling pathway markers in prostate cancer progression
Kremer, C. L., Klein, R. R., Mendelson, J., Browne, W., Samadzedeh, L. K., Vanpatten, K., Highstrom, L., Pestano, G. A., & Nagle, R. B. (2006) · The Prostate · doi:10.1002/pros.20410 · Cited by 182
Pelloski, C. E., Lin, E., Zhang, L., Yung, W. K. A., Colman, H., Liu, J.-L., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2202 · Cited by 179
Castellvi, J., Garcia, A., Rojo, F., Ruiz‐Marcellan, C., Gil, A., Baselga, J., & Ramon y Cajal, S. (2006) · Cancer · doi:10.1002/cncr.22195 · Cited by 177
mTOR Is Activated in the Majority of Malignant Melanomas
Karbowniczek, M., Spittle, C. S., Morrison, T., Wu, H., & Henske, E. P. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701074 · Cited by 168
Activation of the mTOR Signaling Pathway in Renal Clear Cell Carcinoma
Robb, V. A., Karbowniczek, M., Klein-Szanto, A. J., & Henske, E. P. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.08.076 · Cited by 165
mTOR phosphorylated at S2448 binds to raptor and rictor
Rosner, M., Siegel, N., Valli, A., Fuchs, C., & Hengstschläger, M. (2010) · Amino Acids · doi:10.1007/s00726-008-0230-7 · Cited by 162
mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells
Panner, A., James, C. D., Berger, M. S., & Pieper, R. O. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.20.8809-8823.2005 · Cited by 156
McClatchey, A. I. (2007) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.091940 · Cited by 156
Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer
Lin, H.-J., Hsieh, F.-C., Song, H., & Lin, J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602862 · Cited by 155
Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome
Orloff, M. S., & Eng, C. (2008) · Oncogene · doi:10.1038/onc.2008.237 · Cited by 141
Huang, J., Wu, S., Wu, C., & Manning, B. D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0975 · Cited by 129
Self-citationChoi, K. M., McMahon, L. P., & Lawrence, J. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301142200 · Cited by 128
mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer
Zhang, Y., Dai, Q., Sun, D., Xiong, H., Tian, X., Gao, F., Xu, M., Chen, G., Han, Z., & Fang, J. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0555-9 · Cited by 126
Molecular Context of theEGFRMutations: Evidence for the Activation of mTOR/S6K Signaling
Conde, E., Angulo, B., Tang, M., Morente, M. M., Torres‐Lanzas, J., Encuentra, Á. L., López‐Ríos, F., & Sánchez‐Céspedes, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1362 · Cited by 115
Lu, K. H., Wu, W., Dave, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0321 · Cited by 73
Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer
Nozawa, H., Watanabe, T., & Nagawa, H. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.11.008 · Cited by 65
Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy
Dowling, R. J. O., Pollak, M., & Sonenberg, N. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00002 · Cited by 53
Elevated Phospho-S6 Expression Is Associated with Metastasis in Adenocarcinoma of the Lung
McDonald, J. M., Pelloski, C. E., Ledoux, A. A., Sun, M., Raso, G., Komaki, R. K., Wistuba, I. I., Bekele, B. N., & Aldape, K. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0565 · Cited by 38
Cited by
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
Self-citationTargeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Metadata
- Authors
- Menon, S., & Manning, B. D.
- Venue
- Oncogene
- Published
- 2008-12
- Volume
- 27
- Issue
- S2
- Pages
- S43-S51
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2053874502
- Cited by
- 332
- References
- 113
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.